Three Kidney Transplant Recipients Developed Uveal Melanoma
A retrospective report highlighted these rare eye cancer cases in patients following long-term immunosuppression.
Updated on Sept. 23, 2026 in Cancer
Three individuals who underwent kidney transplants were diagnosed with uveal melanoma, a rare form of eye cancer. The findings, documented in a retrospective clinical report, involved patients who required prolonged immunosuppressive therapy following their organ procedures.
Why it matters
Understanding potential malignancy risks in transplant recipients is crucial for long-term monitoring and patient care. This report helps clinicians evaluate rare ocular symptoms that may arise in those requiring chronic immune-system management.
This retrospective report analyzed three renal transplant recipients who developed uveal melanoma, confirmed by biopsy as mixed-cell type. Patients were tracked over a follow-up period of 6 to 83 months, during which no metastatic disease was observed.
The details
Patients in the study presented with choroidal and ciliary body melanoma after years of receiving prolonged immunosuppression to prevent organ rejection. Treatment involved plaque brachytherapy to target the tumors, with one patient also undergoing photodynamic therapy. Complications reported included vision loss resulting from radiation maculopathy and optic neuropathy.
Timeline
The clinical follow-up for the three patients spanned a duration of 6 to 83 months.
Health Landscape
Uveal melanoma is the most common primary intraocular malignancy in adults, yet it remains extremely rare in the general population. This report sits within the broader landscape of managing post-transplant complications, where the necessity of lifelong immunosuppression must be weighed against long-term cancer risks.
If you are a transplant recipient, maintain regular screenings with your transplant team to monitor for any new symptoms or changes in your overall health. Any concerns regarding vision changes or eye health should be discussed with your physician to determine if a referral to an ophthalmologist is necessary.
The takeaway
While uveal melanoma is rare, transplant patients undergoing long-term immunosuppression require vigilant health monitoring. Discuss any new or persistent ocular symptoms with your healthcare provider to ensure appropriate and timely clinical evaluation.
Further reading
For more information on ocular health and oncology, visit our Cancer section.
Source note: This article includes information reported by Nature.
